Dimethylcurcumin
Small moleculeexperimental
Clinical trial activity
2 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00525499)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Androgen ReceptorDEGRADER
Androgen Receptor degrader
Mode of action: degradation enhancer
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(OC)c(OC)c2)cc1OC- Mol. weight
- 396.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL128748 ↗
Also known as
- asc-j9
- asc-j9
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01289574 | Phase 2 | Feb 1, 2011 | AndroScience Corp, Chang Gung University, Government of Taiwan, Orient Europharma Co., Ltd., Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University, TKL Research |
| NCT00525499 | Phase 2 | Aug 1, 2007 | AndroScience Corp |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AndroScience Corp | For profit | 2 | 2 | 1 | 2007 |
| Chang Gung University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Government of Taiwan | Government | 1 | 0 | 1 | 2011 |
| Orient Europharma Co., Ltd. | For profit | 1 | 0 | 1 | 2011 |
| Shin Kong Wu Ho-Su Memorial Hospital | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Taipei Medical University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| TKL Research | For profit | 1 | 0 | 1 | 2011 |
7 organizations
Page 1 / 1